Combined Treatment of Breast Cancer Cell Lines with Vitamin D and COX-2 Inhibitors.
By: Marc Thill, Kathrin Reichert, Alena Woeste, Stephan Polack, Dorothea Fischer, Friederike Hoellen, Achim Rody, Michael Friedrich, Frank Köster

Department of Gynecology and Obstetrics, Agaplesion Markus Hospital, Frankfurt am Main, Germany.
2015-2-11; doi:
Abstract

Background

Vitamin D is known for its anti-cancerogenous potential. Prostaglandin E2 (PGE2) is a proliferation and inflammation activating agent. The production of PGE2 is dependent on the activity of cyclooxygenase-2 (COX-2). A link between vitamin D and PGE2 metabolism was recently shown.

Materials

In MDA-MB-231 and MCF-7 breast cancer cell lines we investigated the influence of calcitriol and the COX-2 inhibitor celecoxib regarding cell growth via MTT test, as well as on the protein and mRNA expression of COX-2 using western blot and qRT-PCR.

Results

The proliferation of MCF-7 and MDA-MB-231 was inhibited by both calcitriol and the COX-2 inhibitor celecoxib and even stronger by their combination. Moreover, calcitriol inhibited the COX-2 protein expression in MDA-MB-231, as well as the COX-2 mRNA expression in both cell lines.

Conclusion

The combination of calcitriol and celecoxib demonstrated a cooperative growth-inhibiting effect in breast cancer cell lines.



Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

PMID:25667510






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements